Moldova – Pharmaceutical products – Achiziționarea medicamentelor oncologice şi imunosupresive necesare instituţiilor medico-sanitare publice (IMSP) pentru anul 2027
Opportunity Score
Confidence: 60%
Complexity: high
37 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation
AI Analysis Summary
Open tender for the procurement of oncological and immunosuppressive medicines for Moldovan public health institutions in 2027, divided into 74 lots. The procedure is conducted by the Centralized Public Procurement Center in Health (CAPCS). Award criteria: lowest price per lot. Electronic submission via SIA RSAP required. Language: Romanian.
Strengths
Documents available
Open procedure
37 days left
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
- Open procedure – operator can bid for all 74 lots.
- Electronic submission mandatory via SIA RSAP (Open portal).
- Language of tender: Romanian.
Buyer
Name
Centrul pentru Achiziții Publice Centralizate în Sănătate
Location
Chișinău, MDA
Identifier
1016601000212
Lots (74)
Ibandronic acid 6 mg/6 ml, injection solution, ATC M05BA06. Quantity: 1930 vials. Estimated value: 2,224,421.50 MDL. Delivery: DDP 2020 with supplier transport throughout 2027; 60% in equal tranches (first within 60 days from contract entry, last by 15 Dec 2027), 40% on order within 20 days.
Lot for pharmaceutical product (medicament) – details not fully provided in structured data.
Lot for pharmaceutical product (medicament) – details not fully provided in structured data.
Procurement Details
Publication
14 Jun 2026
Deadline
22 Jul 2026, 11:00
Procedure
open
Contract
supplies
Language
RON
Publication #
408322-2026
Classification
Performance: MDA
Documents (2)
Opportunity Score
Confidence: 60%
Complexity: high
37 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation